Simple Summary There is currently a lack of useful tests to detect microscopic residual
disease in patients who have undergone surgery to remove their bowel cancer. This inability …

Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease
(MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated …

Background This article reviews the current knowledge on circulating tumor DNA (ctDNA) in
early stage colon cancer and ongoing trials on ctDNA-guided treatment in the adjuvant …

Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in
patients with resected colorectal cancer. Potential utility of circulating tumor DNA (ctDNA) …

Simple Summary After the surgical removal of colorectal cancer (CRC), residual cancer cells
undetectable by standard blood tests and imaging studies are responsible for cancer …

Simple Summary Circulating tumor DNA, or ctDNA, are fragments of tumor DNA that can be
detected in the blood of patients with colorectal cancer. Measuring ctDNA levels in the blood …

Simple Summary Currently, the treatment for localized colon cancer consists of surgery and,
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …

Introduction Colorectal cancer (CRC) is a highly prevalent disease, wherein,~ 30%–40% of
patients with CRC relapse postresection. In some patients with CRC, adjuvant …